ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare ANI Pharmaceuticals to similar companies based on the strength of its profitability, dividends, risk, valuation, earnings, institutional ownership and analyst recommendations.
Earnings and Valuation
This table compares ANI Pharmaceuticals and its peers gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| ANI Pharmaceuticals | $883.37 million | $78.34 million | 14.23 |
| ANI Pharmaceuticals Competitors | $16.51 billion | $3.17 billion | 562.76 |
ANI Pharmaceuticals’ peers have higher revenue and earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk
Analyst Ratings
This is a summary of recent ratings and recommmendations for ANI Pharmaceuticals and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ANI Pharmaceuticals | 0 | 4 | 3 | 0 | 2.43 |
| ANI Pharmaceuticals Competitors | 7844 | 13796 | 25806 | 1039 | 2.41 |
ANI Pharmaceuticals currently has a consensus price target of $100.00, suggesting a potential upside of 39.98%. As a group, “Pharmaceuticals” companies have a potential upside of 24.64%. Given ANI Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe ANI Pharmaceuticals is more favorable than its peers.
Insider & Institutional Ownership
76.0% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares ANI Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ANI Pharmaceuticals | 11.22% | 28.34% | 11.18% |
| ANI Pharmaceuticals Competitors | -2,398.26% | -203.62% | -15.08% |
Summary
ANI Pharmaceuticals beats its peers on 7 of the 13 factors compared.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. Its portfolio includes products in areas such as rare disease, specialty care and established brands, alongside a range of generic drugs. The company’s rare-disease portfolio includes Purified Cortrophin Gel, a prescription medicine used to treat certain inflammatory and other conditions. ANI also produces and markets complex and specialty generics, which can require more involved development or manufacturing than conventional generic drugs.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
